|1.||Gordon, Gary B: 6 articles (07/2013 - 09/2005)|
|2.||Krivoshik, Andrew: 6 articles (07/2013 - 08/2006)|
|3.||Cohn, Susan L: 5 articles (06/2014 - 08/2006)|
|4.||Maris, John M: 5 articles (06/2014 - 08/2006)|
|5.||Fox, Elizabeth: 5 articles (06/2014 - 08/2006)|
|6.||Balis, Frank M: 5 articles (06/2014 - 08/2006)|
|7.||Medina, Diane: 5 articles (07/2013 - 05/2006)|
|8.||Adamson, Peter C: 4 articles (06/2014 - 08/2006)|
|9.||Hagey, Anne E: 4 articles (01/2012 - 08/2006)|
|10.||Goodwin, Anne: 3 articles (09/2010 - 08/2006)|
07/01/2009 - "In this study, we investigated the antivascular properties of ABT-751 in a rat subcutaneous tumor model using dynamic contrast-enhanced magnetic resonance imaging. "
08/01/2007 - "ABT-751 is undergoing Phase I trials in children, but has not been evaluated against a range of pediatric tumor models in vivo. "
09/01/2004 - "The tumor-selective, antivascular effects of ABT-751, a novel, orally active antimitotic agent, currently in phase II clinical development, were characterized in vivo in the present study. "
07/01/2013 - "Forty-seven cancer patients treated with ABT-751 were genotyped for 21 variants in these genes. "
01/01/2010 - "Effects of ABT-751 on polymerization and microtubule structure were time- and dose-dependent but not dependent on tumor type."
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/01/2008 - "A phase II study of ABT-751 in patients with advanced non-small cell lung cancer."
06/01/2008 - "To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC). "
01/01/2012 - "A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients."
03/10/2011 - "We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non-small-cell lung cancer (NSCLC). "
03/10/2011 - "Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer."
05/01/2007 - "Treatment of HCT-116 colon carcinoma tumors with ABT-751, concurrent with the radiation treatment, was able to both enhance radiation-induced tumor regression, and delay the time to recurrence and progression. "
05/01/2007 - "Efficacy of ABT-751, in combination with cisplatin, 5-FU, and radiation, was evaluated in the Calu-6 NSCLC, HT-29 colon, and HCT-116 colon carcinoma xenograft models, respectively. "
01/01/2010 - "In children treated with ABT-751, the EFS is longer in children with neuroblastoma as compared to other diagnoses. "
01/01/2010 - "The ABT-751 IC(50) was 0.6-2.6 mcM in neuroblastoma and 0.7-4.6 mcM in other solid tumor cell lines. "
01/01/2010 - "Patients with neuroblastoma (n = 50) or other solid tumors (n = 26) enrolled on the ABT-751 pediatric phase I and pilot trials were reviewed. "
09/01/2010 - "Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m(2)/day) on a 7-day or 21-day schedule. "
09/01/2010 - "To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. "
02/15/2008 - "Fatigue, hematologic, and gastrointestinal toxicities limited the tolerability of ABT-751 administered to children on the once daily for 21 days every 28 days schedule. "
05/01/2006 - "However, six of seven patients reported grade 3 toxicity (ileus, constipation, abdominal pain, or fatigue), which occurred in cycle 2 or 3. ABT-751 was absorbed after oral administration with an overall mean T(max) of about 2 hours. "
01/01/2012 - "MTD was ABT-751 125 mg orally twice daily for 7 days with carboplatin AUC 6. DLTs included fatigue, ileus, neutropenia and pneumonitis. "
03/10/2011 - "The recommended phase II dose of ABT-751 with pemetrexed is 200 mg. Fatigue, constipation, anemia, nausea, and diarrhea were the most common toxicities in both study arms. "
|8.||thymidine 5'-triphosphate (TTP)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Drug Therapy (Chemotherapy)